Clinical Trials at SCRI Oncology Partners

As of June 2026, 135 paid clinical trials are recruiting at SCRI Oncology Partners, located at SCRI Oncology Partners, 335 24th Ave N #200, Nashville, TN 37203, phone (615) 329-7640 in Nashville, Tennessee. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

135 clinical trials at SCRI Oncology Partners

·Clear filters·↓ Download CSV

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

for Advanced/Metastatic Solid Tumors

21 locations incl. Duarte

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07090499·Phase 1·Recruiting

Apply to this trial

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

for Multiple Myeloma, Newly Diagnosed

11 locations incl. Birmingham

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 19+

Code: NCT06974786·Phase 2·Recruiting

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

for Breast Cancer

102 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07062965·Phase 3·Recruiting

Apply to this trial

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

for Gynecologic Cancers

8 locations incl. Teaneck

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT07024784·Phase 2·Recruiting

Apply to this trial

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

for Breast Neoplasms

33 locations incl. Daphne

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07060807·Phase 3·Recruiting

Apply to this trial

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

for Non-small Cell Lung Cancer

22 locations incl. Glendale

Sponsor: Nuvalent Inc.

Sex: All·Age: 18+

Code: NCT06765109·Phase 3·Recruiting

Apply to this trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

for Breast Cancer

134 locations incl. Daphne

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06966453·Phase 1, Phase 2·Recruiting

Apply to this trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

for Pancreatic Ductal Adenocarcinoma

13 locations incl. Los Angeles

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07020221·Phase 1, Phase 2·Recruiting

Apply to this trial

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

for Lymphoma

6 locations incl. Palo Alto

Sponsor: Treeline Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT07082803·Phase 1·Recruiting

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for Prostate Cancer

50 locations incl. Phoenix

Sponsor: Merck Sharp & Dohme LLC

Sex: Male·Age: 18+

Code: NCT06925737·Phase 3·Recruiting

Apply to this trial

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

for Triple Negative Breast Cancer

9 locations incl. Los Angeles

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT06926920·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

for Locally Advanced/Metastatic Solid Tumors

5 locations incl. Denver

Sponsor: InSilico Medicine Hong Kong Limited

Sex: All·Age: 18+

Code: NCT06414460·Phase 1·Recruiting

Apply to this trial

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

for Carcinoma, Non-Small-Cell Lung

Drug: Adagrasib

54 locations incl. Birmingham

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT06875310·Phase 3·Recruiting

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

for Hepatocellular Cancer

10 locations incl. Duarte

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06858813·Phase 1·Recruiting

Apply to this trial

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for Lymphoma, Large B-Cell, Diffuse

Drug: Polatuzumab Vedotin

70 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06890884·Phase 2·Recruiting

Apply to this trial

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

for Advanced HR+/HER2- Breast Cancer

8 locations incl. Los Angeles

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT06726148·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

for Metastatic Solid Tumor

20 locations incl. Tucson

Sponsor: Coherus Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06657144·Phase 1·Recruiting

Apply to this trial

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

for Esophageal Squamous Cell Carcinoma

6 locations incl. Fullerton

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06644781·Phase 3·Recruiting

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

85 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting

Apply to this trial

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

for Advanced Solid Tumors

5 locations incl. Sarasota

Sponsor: Accent Therapeutics

Sex: All·Age: 18+

Code: NCT06799065·Phase 1·Recruiting

Apply to this trial

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

for MTAP-deleted Solid Tumors

17 locations incl. Birmingham

Sponsor: Bayer

Sex: All·Age: 18+

Code: NCT06914128·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

for Breast Neoplasms

8 locations incl. Santa Monica

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06797635·Phase 2·Recruiting

Apply to this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

38 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting

Apply to this trial

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

for Limited Stage Small Cell Lung Cancer

Drug: Durvalumab

33 locations incl. Daphne

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT06773910·Phase 2·Recruiting

Apply to this trial

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

for Extensive-Stage Small Cell Lung Cancer

Drug: Atezolizumab

20 locations incl. Daphne

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06646276·Phase 3·Recruiting

Apply to this trial

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

for Prostate Cancer Metastatic Disease

10 locations incl. Denver

Sponsor: Halda Therapeutics OpCo, Inc.

Sex: Male·Age: 18+

Code: NCT06800313·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

for Advanced Solid Tumors

11 locations incl. Birmingham

Sponsor: Bayer

Sex: All·Age: 18+

Code: NCT06760819·Phase 2·Recruiting

Apply to this trial

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for Non-Small Cell Lung Cancer

Drug: Telisotuzumab Vedotin

38 locations incl. Chandler

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06568939·Phase 2·Recruiting

Apply to this trial

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

for Breast Cancer

17 locations incl. Prescott

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06695845·Phase 2·Recruiting

Apply to this trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

for Melanoma, Cutaneous Malignant

40 locations incl. Phoenix

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT06743126·Phase 3·Recruiting

Apply to this trial

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

for Malignant Mesothelioma

6 locations incl. Denver

Sponsor: InSilico Medicine Hong Kong Limited

Sex: All·Age: 18+

Code: NCT06566079·Phase 1·Recruiting

Apply to this trial

A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

for Solid Tumor

Drug: PT0253

7 locations incl. Boston

Sponsor: PAQ Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06797336·Phase 1·Recruiting

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

Drug: Amivantamab

150 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting

Apply to this trial

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

for Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

7 locations incl. Sarasota

Sponsor: Olema Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06784193·Phase 1·Recruiting

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

Drug: Amivantamab

70 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

for Solid Tumor

12 locations incl. La Jolla

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT06619587·Phase 1·Recruiting

Apply to this trial

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

for Solid Tumor, Adult

19 locations incl. Duarte

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06625775·Phase 1·Recruiting

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

Drug: Amivantamab

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting

Apply to this trial

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

for Breast Cancer

13 locations incl. Tucson

Sponsor: Processa Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06568692·Phase 2·Recruiting

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

165 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting

Apply to this trial